Format

Send to

Choose Destination
Rev Alerg Mex. 2018 Jan-Mar;65(1):108-116. doi: 10.29262/ram.v65i1.314.

[Identification of new mutations in TCIRG1 as a cause of infantile malignant osteopetrosis in two Mexican patients].

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Secretaría de Salud, Instituto Nacional de Pediatría, Unidad de Investigación en Inmunodeficiencias, Ciudad de México, México. blancas.lizbeth@gmail.com.

Abstract

in English, Spanish

BACKGROUND:

Osteopetrosis is a heterogeneous group of diseases that are characterized by increased bone density due to abnormalities in osteoclast differentiation or function, which result in a lack of bone resorption.

CASE REPORTS:

Two patients with osteopetrosis onset since the first months of life, with facial dysmorphia, blindness, deafness, hepatosplenomegaly, hypotonia, neurodevelopmental retardation and bicytopenia. Bone radiographs showed osteosclerosis. They were assessed by different specialists prior to definitive diagnosis. Genetic analysis determined mutations in the TCIRG1 gene. Patient 1 had a homozygous mutation for p.Ile720Alafs*14 identified, which hasn't been previously reported. Patient 2 had a compound heterozygous mutation: the first one, p.Phe459Leufs*79, and the second one, p.Gly159Argfs*68, none of which has been previously reported as far as we know.

CONCLUSION:

The only therapeutic option for patients with osteopetrosis is hematopoietic stem cell transplantation (HSCT), which should be carried out in the course of the first 3 months of life, before neurological damage occurs. Although osteopetrosis diagnosis is relatively simple, it is delayed owing to the lack of clinical suspicion.

KEYWORDS:

Hematopoietic stem cell transplantation; Infantile malignant osteopetrosis; Osteosclerosis; TCIRG1

PMID:
29723947
DOI:
10.29262/ram.v65i1.314

Supplemental Content

Loading ...
Support Center